PROTEOSTASIS THERAPEUTICS, INC.
About Proteostasis Therapeutics, Inc.
We are an
innovative, clinical stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis, or CF, and other diseases caused by an imbalance in the proteostasis network, a set of pathways that
control protein biosynthesis, folding, trafficking and clearance. We focus on identifying therapies that restore protein function. CF is a disease caused by defects in the function or abundance of cystic fibrosis transmembrane conductance regulator,
or CFTR. Our CF focused pipeline consists of novel CFTR modulators including correctors, potentiators and amplifiers. Upon discovery of amplifiers, a novel class of CFTR modulators, we have exploited its novel mechanism of action as a drug screening
tool and have subsequently identified correctors and potentiators to be developed as part of combination therapies. Investigational agents representative of all three classes of CFTR modulators are currently in clinical development and include
PTI-428,
a CFTR amplifier,
and PTI-801
a third generation CFTR corrector, and
PTI-808,
a CFTR potentiator. We believe that both
PTI-428
and
PTI-801
have potential as
add-on
therapy to current and future
standard-of-care
CFTR modulator treatments. Additionally, we are pursuing proprietary dual combination of
PTI-801
and
PTI-808,
and triple combination of
PTI-801,
PTI-808
and
PTI-428
as product opportunities. We are developing and, if approved, intend to
commercialize our own therapies, including
add-on
and combination therapies for CF patients who have at least one F508del mutation, representing the majority of the patient population.
Corporate Information
We were incorporated in Delaware
on December 13, 2006 under the name Proteoguard, Inc. and subsequently changed our name to Proteostasis Therapeutics, Inc. on September 17, 2007. Our principal executive offices are located at 80 Guest Street, Suite 500, Boston,
Massachusetts, 02135, and our telephone number is
(617) 225-0096. Our
website address is www.proteostasis.com. We do not incorporate the information on or accessible through our website into this
prospectus, and you should not consider any information on, or that can be accessed through, our website a part of this prospectus.
This prospectus
contains references to our trademarks and to trademarks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork, and other visual displays, may appear without the
®
or symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the
applicable licensor to these trademarks and trade names. We do not intend our use or display of other companies trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
On February 17, 2016, we completed our initial public offering. We qualify as an emerging growth company as defined in the Jumpstart Our
Business Startups Act of 2012, as amended, or the JOBS Act. As an emerging growth company, we may take advantage of specified reduced disclosure and other requirements that are otherwise applicable generally to public companies. We would cease to be
an emerging growth company on the date that is the earliest of: (i) the last day of the fiscal year in which we have total annual gross revenues of $1.07 billion or more; (ii) December 31, 2021; (iii) the date on which we have
issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated filer under the rules of the SEC.
The public may read and copy any materials we file with the SEC at the SECs Public Reference Room at 100 F Street, NE, Washington, DC 20549. The public
may obtain information of the Public Reference Room by calling the SEC at
1-800-SEC-0330.
The SEC maintains a website that
contains the materials we file with the SEC at www.sec.gov.
2